Țară: Canada
Limbă: engleză
Sursă: Health Canada
OLMESARTAN MEDOXOMIL
JAMP PHARMA CORPORATION
C09CA08
OLMESARTAN MEDOXOMIL
40MG
TABLET
OLMESARTAN MEDOXOMIL 40MG
ORAL
30/100
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0152496003; AHFS:
APPROVED
2017-05-01
_JAMP Olmesartan_ _ _ _(olmesartan medoxomil tablets) Product Monograph _ _Page 1 of 30_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR JAMP OLMESARTAN Olmesartan Medoxomil Tablets USP 20 mg, and 40 mg Tablets Oral Angiotensin II AT 1 Receptor Blocker JAMP PHARMA CORPORATION 1310 rue Nobel Boucherville, Quebec J4B 5H3, Canada Date of Initial Authorization: October 26, 2021 Submission Control Number: 247832 _ _ _JAMP Olmesartan_ _ _ _(olmesartan medoxomil tablets) Product Monograph _ _Page 2 of 30_ TABLE OF CONTENTS TABLE OF CONTENTS....................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 4 1 INDICATIONS ........................................................................................................... 4 1.1 Pediatrics ............................................................................................................. 4 1.2 Geriatrics.............................................................................................................. 4 2 CONTRAINDICATIONS ........................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................... 5 4 DOSAGE AND ADMINISTRATION ......................................................................... 5 4.1 Dosing Considerations..................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment .............................................. 6 4.3 Reconstitution................................................................................................... 6 4.4 Administration................................................................................................... 6 4.5 Missed Dose..................................................................................................... 6 5 OVERDOSAGE ............................. Citiți documentul complet